HR Execs on the Move

Pieris

www.pieris.com

 
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pieris.com
  • 255 State Street 9th floor
    Boston, MA USA 02109
  • Phone: 857.246.8998

Executives

Name Title Contact Details
Tom Bures
 Chief Financial Officer Profile
Frank Vollmering
 Vice President, Human Resources Profile

Similar Companies

NovaBioMed Inc

NovaBioMed Inc is a Kentville, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Children's Crisis Treatment Center

CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.

Bracco Diagnostics

Established in August 1994, Bracco Diagnostics Inc. develops and markets a wide range of diagnostic imaging agents in the U.S. Bracco products are currently used in conjunction with X-ray, CT, MRI, and nuclear medicine. Bracco Diagnostics Inc. is a

Critical Outcome Technologies

Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.